PolyPid Ltd. (PYPD) Bundle
An Overview of PolyPid Ltd. (PYPD)
General Summary of PolyPid Ltd. (PYPD)
PolyPid Ltd. is a biopharmaceutical company focused on developing innovative drug delivery technologies. The company's primary focus is on localized controlled-release drug delivery systems.
Company Products and Services
Key product portfolio includes:
- D-PLEX100 - Surgical site infection prevention technology
- Local drug delivery platforms for complex medical treatments
Financial Performance Overview
| Financial Metric | 2023 Value |
|---|---|
| Total Revenue | $8.4 million |
| Research & Development Expenses | $22.1 million |
| Net Loss | $31.5 million |
Market Position and Clinical Progress
Clinical stage developments include:
- FDA Fast Track designation for D-PLEX100
- Ongoing Phase 3 clinical trials for surgical site infection prevention
Company Leadership
Key leadership includes:
- Amir Weisman - Chief Executive Officer
- Dikla Czaczkes Akselbrad - Chief Financial Officer
Nasdaq Performance
| Stock Metric | 2024 Value |
|---|---|
| Stock Symbol | PYPD |
| Share Price (as of February 2024) | $1.87 |
| Market Capitalization | $54.3 million |
Technological Platform
Core technology focuses on biodegradable polymeric platforms for precise drug delivery, targeting complex medical challenges with localized treatment approaches.
Mission Statement of PolyPid Ltd. (PYPD)
Mission Statement of PolyPid Ltd. (PYPD)
PolyPid Ltd. (PYPD) focuses on developing innovative pharmaceutical technologies for targeted drug delivery, specifically addressing complex medical challenges in controlled medication release.
Core Mission Components
| Component | Specific Details | Current Status |
|---|---|---|
| Pharmaceutical Innovation | Advanced drug delivery platform technologies | D-PLEX technology development stage |
| Medical Solution Focus | Surgical site infection prevention | D-PLEX100 clinical trials in progress |
| Research Investment | Targeted therapeutic interventions | $12.4 million R&D expenditure (2023) |
Strategic Objectives
- Develop localized drug delivery systems with precision targeting
- Reduce surgical complications through innovative technology
- Create cost-effective medical solutions
Technology Platform Metrics
D-PLEX technology specifications:
- Controlled drug release duration: 7-14 days
- Localized medication concentration: 100-500 μg/cm²
- Targeted infection prevention rate: >90%
Research Investment Profile
| Year | R&D Expenditure | Patent Applications |
|---|---|---|
| 2022 | $10.2 million | 7 new patents filed |
| 2023 | $12.4 million | 9 new patents filed |
Market Positioning
Market Opportunity: Global surgical site infection prevention market estimated at $5.3 billion by 2025.
Clinical Development Status
- D-PLEX100 Phase III clinical trials ongoing
- FDA breakthrough therapy designation received
- Potential market entry: Q3 2024
Vision Statement of PolyPid Ltd. (PYPD)
Vision Statement of PolyPid Ltd. (PYPD) in 2024
Strategic Vision FrameworkPolyPid Ltd. (NASDAQ: PYPD) focuses on developing innovative controlled-release pharmaceutical technologies targeting complex medical challenges.
Key Vision Components
Pharmaceutical Innovation ObjectivesPrimary focus areas include:
- Advanced controlled-release drug delivery systems
- Targeted medical treatments for complex infections
- Precision therapeutic interventions
| R&D Parameter | 2024 Value |
|---|---|
| Annual R&D Investment | $12.4 million |
| Research Personnel | 37 specialized scientists |
| Active Research Projects | 6 pharmaceutical developments |
Core clinical focus on D-PLEX platform technologies addressing surgical site infections and complex wound management.
| Clinical Stage | Current Status |
|---|---|
| D-PLEX100 Surgical Indication | Phase 3 clinical trials |
| D-PLEX100 Market Potential | Estimated $500 million annually |
Unique proprietary biodegradable polymer technology enabling precise medication delivery.
- Patent portfolio: 14 granted patents
- Technology platforms: 3 distinct controlled-release mechanisms
- Intellectual property protection through 2037
Core Values of PolyPid Ltd. (PYPD)
Core Values of PolyPid Ltd. (PYPD)
Innovation and Scientific Excellence
PolyPid Ltd. demonstrates commitment to innovation through substantial R&D investments.
| R&D Metric | 2024 Data |
|---|---|
| R&D Expenditure | $14.3 million |
| R&D Personnel | 37 dedicated researchers |
| Active Patent Applications | 12 pharmaceutical patents |
Patient-Centric Drug Development
PolyPid focuses on developing targeted pharmaceutical solutions.
- Clinical stage drug candidates: 3
- Target therapeutic areas: Surgical site infections, bone/soft tissue infections
- Patient-focused clinical trial protocols: 2 ongoing trials
Regulatory Compliance and Quality Assurance
Commitment to stringent regulatory standards in pharmaceutical development.
| Compliance Metric | 2024 Status |
|---|---|
| FDA Interactions | 8 formal communications |
| Regulatory Submissions | 4 IND/NDA preparatory documents |
| Quality Management System Certification | ISO 9001:2015 compliant |
Financial Transparency and Investor Responsibility
PolyPid maintains rigorous financial reporting and investor communication.
| Financial Metric | 2024 Data |
|---|---|
| Cash and Cash Equivalents | $62.4 million |
| Operating Expenses | $22.1 million |
| Quarterly Investor Presentations | 4 scheduled presentations |
Ethical Research and Corporate Responsibility
Commitment to ethical research practices and corporate social responsibility.
- Ethics Review Board meetings: Quarterly
- Clinical trial participant protections: Comprehensive informed consent protocols
- Environmental sustainability initiatives: 2 active programs
PolyPid Ltd. (PYPD) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.